• Sonuç bulunamadı

Perspectives from The European Society of Cardiology Congress 2014

N/A
N/A
Protected

Academic year: 2021

Share "Perspectives from The European Society of Cardiology Congress 2014"

Copied!
1
0
0

Yükleniyor.... (view fulltext now)

Tam metin

(1)

Invited Editorial

Perspectives from The European Society of

Cardiology Congress 2014

575

The European Society of Cardiology Congress took place in Barcelona between August 30 and September 3 with an atten-dance of 30000 delegates. The sessions were planned in nine different topics and were placed in nine villages according to the topic like the previous years. According to the database of European Society of Cardiology, more than 400 delegates from Turkey attended. There was a record number of abstract sub-missions this year. There were 11,444 submitted abstracts and only 4597 were accepted. From Turkey, 411 abstracts were submitted. Of these, 73 were accepted. Compared to last year, the submission rate was higher since last year only 145 abstracts were submitted and 59 of them accepted. The number of abstracts that were accepted did not increase parallel to the increased submission this year. However the increase in sub-mission rates can stil be considered a positive development considering the low acceptance rates this year. In 2014, there were overall 1583 abstract reviewers and 22 of them were from Turkey. This number had increased from last year when there were 13 reviewers from Turkey. In the Scientific Program, ten speakers from Turkey were either chairing or speaking in a ses-sion. This number unfortunatey did not increase compared to last year.

Turkish Society of Cardiology members constitute 4% of the European Society of Cardiology members. Overall there are 56 member countries. Of these countries, Turkey comes eighth when we rank according to the number of members. However, when we look at the members of the of working groups or asso-ciations of the European Society of Cardiology, these numbers are not reflected proportionately. Only 905 members of the Turkish Society of Cardiology are active members in these bod-ies of the ESC.

When we look at the administrative and leadership part of the ESC and constituent bodies, the representation of Turkey is also suboptimal. This year Prof. Dr. Çetin Erol has been elected

to the Board of the European Society of Cardiology. This is a huge success and opportunity for Turkey. In addition, Prof. Dr. Bülent Görenek, Prof. Dr. Lale Tokgözoğlu, Prof. Dr. Cemil İzgi, Prof. Dr. Serap Erdine, Prof. Dr. Murat Uğurlucan and Prof. Dr. Öztekin Oto are serving at the different Boards of the Associations or Working Groups of the European Society of Cardiology.

These numbers show us that Turkey has not reached its potential either scientifically or administratively in the European Society of Cardiology and is not where it deserves to be. We need to be more proactive and work harder to increase this representation in the upcoming years. We should aim to pro-duce higher quality Science, be more active in our fields of inter-est and be more involved in ESC activities. It is the mission and responsibility of The Turkish Society of Cardiology and its work-ing groups to encourage, educate and support young Cardiologists, provide them with opportunities for education and research. We should not only do our best for this mission but also be role models for the next generation.

Prof. Dr. Lale Tokgözoğlu FACC, FESC President, Turkish Society of Cardiology

Address for Correspondence: Prof. Dr. Lale Tokgözoğlu, Hacettepe Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Sıhhıye, Ankara-Türkiye Phone: +90 312 305 17 83 E-mail: laletok2@gmail.com

Referanslar

Benzer Belgeler

This effectively means that metformin stays as the first-line drug in patients with T2DM without CVD, and in patients at moderate CV risk, while in patients at high/very-high CV

Recent guidelines upgraded the class of recommendation to IIa and state that beta-blockers or non-dihydropyridine calcium-chan- nel blockers (in the absence of HFrEF) should

Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in

(Ivabradine in stable coronary artery disease without clinical heart failure) SIGNIFY (4): 19.102 patients with stable coronary artery disease having resting heart rate of >70

Evaluation of right ventricular functions using myocardial performance index in patients with asymptomatic mitral stenosis. Koroner kalp hastalığı ve hipertansiyonu

Her ne kadar yardımcı ilaç tedavisi ACLS’nin halen bir parçası olsa da, 2005 de ileri yaşam desteğinde (ALS) vurgu temellere döndü, ne çalıştığı bilinenler üzerine

Üç yüz on beş hastayı kapsayan ARBITER-6 HALTS çalışmasın- da (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6: HDL and LDL

The main goals of this pioneering effort are, therefore, already quite clear: to increase collaboration among NSCJ Editors, enhance editorial standards, improve quality